Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BCL006
MIFTS: 64

B-Cell Lymphomas

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for B-Cell Lymphomas

About this section

MalaCards integrated aliases for B-Cell Lymphomas:

Name: B-Cell Lymphomas 39 77 74
Lymphoma, B-Cell 54 13 45 41
B-Cell Lymphoma 12 54 30 15
B-Cell Lymphocytic Neoplasm 12
Lymphoma B-Cell 56

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:707
MeSH 45 D016393
NCIt 51 C27907 C3457
SNOMED-CT 69 1929004
UMLS 74 C0079731
Sources

Summaries for B-Cell Lymphomas

About this section
NIH Rare Diseases : 54 B-cell lymphoma refers to types of non-Hodgkin lymphoma that are characterized by abnormalities of the "B-cells" (a type of white blood cell that makes antibodies to help fight infection). The condition may grow and spread slowly with few symptoms (also known as indolent lymphoma) or may be very aggressive with severe symptoms. When present, signs and symptoms may include swollen lymph nodes in the neck, armpit, or groin; abdominal pain; fatigue; fever; night sweats; and/or weight loss. The underlying cause of B-cell lymphoma is poorly understood. However, the condition can be associated with genetic abnormalities, environmental factors, viruses, immunodeficiency states, and connective-tissue disorders. Treatment is based on many factors, including the severity of the condition and the associated signs and symptoms.

MalaCards based summary : B-Cell Lymphomas, also known as lymphoma, b-cell, is related to nodal marginal zone b-cell lymphoma and primary cutaneous marginal zone b-cell lymphoma. An important gene associated with B-Cell Lymphomas is MIR17 (MicroRNA 17), and among its related pathways/superpathways are T cell receptor signaling pathway and Development EGFR signaling pathway. The drugs Prednisolone phosphate and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A non-Hodgkin lymphoma that has material basis in B cells.

Wikipedia : 77 Lymphoma is a group of blood cancers that develop from lymphocytes (a type of white blood cell). The... more...

Sources

Related Diseases for B-Cell Lymphomas

About this section

Diseases in the B-Cell Lymphomas family:

T-Cell Lymphoma 1a

Diseases related to B-Cell Lymphomas via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 721)
# Related Disease Score Top Affiliating Genes
1 nodal marginal zone b-cell lymphoma 34.8 BCL6 MALT1
2 primary cutaneous marginal zone b-cell lymphoma 34.8 BCL10 IRF4 MALT1
3 relapsed/refractory diffuse large b-cell lymphoma 34.8 FOXP1 IRF4
4 t-cell/histiocyte rich large b cell lymphoma 34.8 BCL6 MME
5 primary mediastinal large b-cell lymphoma 34.8 BCL6 FOXP1 IRF4 MYC
6 marginal zone b-cell lymphoma 34.7 BCL10 BCL6 CCND1 FOXP1 IRF4 MALT1
7 intravascular large b-cell lymphoma 34.6 BCL6 MME
8 diffuse large b-cell lymphoma 34.6 BCL10 BCL6 FOXP1 HOTAIR IRF4 MALT1
9 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 34.4 BCL6 MYC
10 lymphoma, mucosa-associated lymphoid type 34.2 BCL10 BCL6 CCND1 FOXP1 IRF4 MALT1
11 splenic marginal zone lymphoma 33.6 BCL6 MALT1 PAX5
12 follicular lymphoma 33.3 BCL10 BCL6 CCND1 IRF4 MME MYC
13 primary effusion lymphoma 33.2 BCL6 IRF4 MYC
14 reticulosarcoma 32.7 BCL6 CCND3 PAX5
15 mature b-cell neoplasm 32.7 BCL6 MME MYC PVT1
16 burkitt lymphoma 32.4 BCL6 CCND3 MME MYC PAX5 PVT1
17 lymphoma 32.4 BCL10 BCL6 CCND1 GAS5 MALT1 MYC
18 leukemia, chronic lymphocytic 31.4 BCL10 BCL6 CCND1 PAX5
19 lymphoma, hodgkin, classic 31.3 BCL6 MIR20A MME PAX5 PVT1
20 nodular lymphocyte predominant hodgkin lymphoma 31.3 BCL6 PAX5
21 lymphocytic leukemia 31.2 HOTAIR MME MYC PAX5
22 composite lymphoma 31.1 BCL6 PAX5
23 plasmacytoma 31.0 IRF4 MYC PVT1
24 chromosomal triplication 31.0 BCL6 MALT1
25 central nervous system lymphoma 31.0 BCL6 FOXP1 MALT1
26 cll/sll 30.9 CCND1 MME PAX5
27 follicular lymphoma 1 30.8 BCL10 BCL6
28 bladder lymphoma 30.7 MME PAX5
29 lymphoma, non-hodgkin, familial 30.6 BCL10 BCL6 CCND1 CCND3 CDKN1B IRF4
30 lung lymphoma 30.4 BCL6 MALT1 PAX5
31 intestinal disease 30.4 BCL6 CCND1 MYC
32 mantle cell lymphoma 30.3 BCL6 CCND1 CCND3 CDKN1B GAS5 MALAT1
33 retinoblastoma 30.1 CCND1 CCND3 HOTAIR MALAT1
34 leukemia, acute myeloid 29.5 HOTAIR MALAT1 MME MYC TUG1
35 squamous cell carcinoma 29.4 CCND1 CDKN1B HOTAIR MALAT1 TUG1
36 thyroid cancer, nonmedullary, 1 29.3 GAS5 HOTAIR MALAT1 PVT1
37 cholangiocarcinoma 29.2 CCND1 CDKN1B MALAT1 MME TUG1
38 small cell cancer of the lung 29.1 HOTAIR MALAT1 MYC PAX5 TUG1
39 thyroid cancer 29.1 CCND1 CDKN1B GAS5 HOTAIR MALAT1 MYC
40 nasopharyngeal carcinoma 28.9 CCND1 GAS5 HOTAIR MALAT1 MYC PVT1
41 glioblastoma 28.9 CCND1 CDKN1B GAS5 HOTAIR MALAT1 MYC
42 myeloma, multiple 28.8 CCND1 CCND3 GAS5 HOTAIR IRF4 MALAT1
43 lung cancer susceptibility 3 28.8 CCND1 GAS5 HOTAIR MALAT1 TUG1
44 renal cell carcinoma, nonpapillary 28.6 GAS5 HOTAIR MALAT1 MME PVT1 TUG1
45 osteogenic sarcoma 28.4 GAS5 HOTAIR MALAT1 PVT1 TUG1
46 ovarian cancer 28.3 CCND1 CDKN1B GAS5 HOTAIR MALAT1 MYC
47 bladder cancer 28.2 CCND1 GAS5 HOTAIR MALAT1 MYC PVT1
48 glioma 28.1 CCND1 GAS5 HOTAIR MALAT1 MIR17 MIR20A
49 hepatocellular carcinoma 28.0 CCND1 GAS5 HOTAIR MALAT1 MIR20A MYC
50 breast cancer 28.0 CCND1 CCND3 CDKN1B GAS5 HOTAIR MALAT1

Graphical network of the top 20 diseases related to B-Cell Lymphomas:



Diseases related to B-Cell Lymphomas
Sources

Symptoms & Phenotypes for B-Cell Lymphomas

About this section

MGI Mouse Phenotypes related to B-Cell Lymphomas:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.85 BCL10 BCL6 CCND1 CCND3 CDKN1B IRF4
2 immune system MP:0005387 9.7 BCL10 BCL6 CCND1 CCND3 CDKN1B IRF4
3 neoplasm MP:0002006 9.1 CCND1 CCND3 CDKN1B IRF4 MYC PAX5
Sources

Drugs & Therapeutics for B-Cell Lymphomas

About this section

Drugs for B-Cell Lymphomas (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 641)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
2
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
3
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2068-78-2, 57-22-7 5978
4
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
6
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
7
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
8
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
9
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
10
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1177-87-3
11
Gemcitabine Approved Phase 4,Phase 2,Phase 3,Phase 1 95058-81-4 60750
12
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4, 65-46-3 6253
13
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
14
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
15
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
16
Epirubicin Approved Phase 4,Phase 3,Phase 2,Not Applicable 56420-45-2 41867
17
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
18
Tenofovir Approved, Experimental, Investigational Phase 4,Phase 2 147127-20-6 464205
19
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
20
Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
21
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
22
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 3778-73-2 3690
23
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 53643-48-4, 59917-39-4 40839
24
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
25
Decitabine Approved, Investigational Phase 4,Phase 1,Phase 2,Early Phase 1 2353-33-5 451668
26
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-03-3
27
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 5754
28
Azacitidine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 320-67-2 9444
29
Ribavirin Approved Phase 4,Phase 3 36791-04-5 37542
30
Sofosbuvir Approved Phase 4,Phase 2 1190307-88-0 45375808
31
Ledipasvir Approved Phase 4,Phase 2 1256388-51-8 67505836
32
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
33
Tyrosine Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 60-18-4 6057
34
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2920-86-7
35
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 31703
36 Prednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Methylprednisolone Acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2079)
# Name Status NCT ID Phase Drugs
1 Treatment of Diffuse Large B Cell Lymphoma Unknown status NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
2 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
3 To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Unknown status NCT02585947 Phase 4 Tenofovir
4 Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma Completed NCT03376958 Phase 4 Apatinib
5 LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
6 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
7 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
8 Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma Recruiting NCT03513601 Phase 4 (R)-CHOP regimen;(R)-CVP regimen
9 A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma Recruiting NCT03579082 Phase 4 Decitabine
10 Reduced Chemotherapy in Low Risk DLBCL Recruiting NCT02752815 Phase 4 Rituximab;Cyclophosphamide;Epirubicin;Vincristine;Prednisone
11 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
12 A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma Active, not recruiting NCT01990534 Phase 4 Brentuximab vedotin
13 Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. Enrolling by invitation NCT03229200 Phase 4 Ibrutinib
14 Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma Not yet recruiting NCT02992834 Phase 4
15 Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study Terminated NCT02717949 Phase 4 sofosbuvir/ledipasvir;sofosbuvir;Ribavirin
16 Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients Unknown status NCT00846157 Phase 3
17 Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma Unknown status NCT00499018 Phase 3 Rituximab;Ciclofosfamide;Doxorubicina;Vincristina;Prednisone;Pegfilgrastim;Mitoxantrone;ARA-C;Lenograstim;BCNU;ARA-C;VP-16;Ciclofosfamide;Doxorubicina;Vincristina
18 R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCL Unknown status NCT03151044 Phase 3 High-dose Epirubicin Combined with CVP ± Rituximab;Standard-dose Epirubicin Combined with CVP ± Rituximab
19 A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients Unknown status NCT02867566 Phase 3 IBI301 plus CHOP;Rituximab plus CHOP
20 MabionCD20® Compared to MabThera® in Lymphoma Patients Unknown status NCT02617485 Phase 3 Rituximab;Doxorubicin;Vincristine;Cyclophosphamide;prednisone
21 30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy Unknown status NCT01156259 Phase 3
22 Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions Unknown status NCT02867553 Phase 3 rituximab
23 TREatment of degeNerative and Neoplastic Diseases With Rituximab Unknown status NCT01277172 Phase 2, Phase 3
24 Study Comparing the Zevalin Regimen With no Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R Unknown status NCT00322218 Phase 3 Zevalin Therapeutic Regimen
25 Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP Unknown status NCT01210287 Phase 2, Phase 3 nucleoside analog reverse transcriptase inhibitor
26 Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma Unknown status NCT00003650 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisone;vincristine sulfate
27 Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma Unknown status NCT00022685 Phase 3
28 Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma Unknown status NCT01933711 Phase 3 rituximab
29 Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP Unknown status NCT00725231 Phase 3 chemotherapy
30 Helicobacter – Lymphoma – Radiation Part I: Eradication, Part II: Radiation Unknown status NCT00154440 Phase 3 proton pump inhibitor;clarithromycin;amoxicillin;metronidazole
31 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
32 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
33 Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
34 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
35 Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
36 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
37 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
38 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
39 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
40 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
41 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
42 LMBA02 Protocol for Patients With a Burkitt Lymphoma Unknown status NCT00180882 Phase 3 rituximab
43 Treatment of Mature B-cell Lymphoma/Leukaemia Completed NCT00162656 Phase 3 half cyclophosphamide;without COPADM3;mini CYVE, without 3 maintenance courses;LMB B;LMB C
44 Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Completed NCT01197560 Phase 2, Phase 3 Lenalidomide;Gemcitabine;Oxaliplatin;Rituximab;Etoposide
45 Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy Completed NCT00790036 Phase 3 Everolimus;Everolimus Placebo
46 Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203) Completed NCT00147121 Phase 2, Phase 3 Rituximab + Standard CHOP;Rituximab + Bi-weekly CHOP
47 A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a Completed NCT01724021 Phase 3 Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP);Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP);Bendamustine;Rituximab;Rituximab;Rituximab;Rituximab
48 A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13 Completed NCT00400478 Phase 3 Rituximab
49 A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib Completed NCT01324596 Phase 3 Intravenous;Bortezomib
50 ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1 Completed NCT00140595 Phase 3 rituximab;doxorubicin;cyclophosphamide

Search NIH Clinical Center for B-Cell Lymphomas

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about B-Cell Lymphomas cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for B-Cell Lymphomas:
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to B-Cell Lymphomas:
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells

Cochrane evidence based reviews: lymphoma, b-cell

Sources

Genetic Tests for B-Cell Lymphomas

About this section

Genetic tests related to B-Cell Lymphomas:

# Genetic test Affiliating Genes
1 B-Cell Lymphoma 30
Sources

Anatomical Context for B-Cell Lymphomas

About this section

MalaCards organs/tissues related to B-Cell Lymphomas:

42
B Cells, T Cells, Bone, Bone Marrow, Breast, Lymph Node, Nk Cells
Sources

Publications for B-Cell Lymphomas

About this section

Articles related to B-Cell Lymphomas:

(show top 50) (show all 1569)
# Title Authors Year
1
Epstein-Barr virus LMP2A utilizes Syk and PI3K to activate NF-κB in B-cell lymphomas to increase MIP-1α production. ( 30609049 )
2019
2
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. ( 30707764 )
2019
3
Primary cutaneous large B-cell lymphomas: relevance of the 2017 World Health Organization classification: clinicopathological and molecular analyses of 64 cases. ( 30715765 )
2019
4
MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. ( 30723112 )
2019
5
LMO2 Negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas: Erratum. ( 30724749 )
2019
6
Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP. ( 30755497 )
2019
7
Porpaczy E, Tripolt S, Hoelbl-Kovacic A, et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood. 2018;132(7):694-706. ( 30765499 )
2019
8
Origin and Pathogenesis of B Cell Lymphomas. ( 30779028 )
2019
9
Stereotyped B Cell Receptor Immunoglobulins in B Cell Lymphomas. ( 30779034 )
2019
10
RNA Sequencing in B-Cell Lymphomas. ( 30779040 )
2019
11
HDAC3 inhibition up-regulates PD-L1 expression in B-cell lymphomas and augments the efficacy of anti-PD-L1 therapy. ( 30824609 )
2019
12
Growth-inhibition of cell lines derived from B cell lymphomas through antagonism of serotonin receptor signaling. ( 30862884 )
2019
13
Molecular pathogenesis of germinal center-derived B cell lymphomas. ( 30874347 )
2019
14
Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders. ( 30899698 )
2019
15
The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas. ( 30916801 )
2019
16
Monoclonal antibody-drug conjugates in B-cell lymphomas. ( 30935954 )
2019
17
Chromatin remodeling factor lymphoid-specific helicase links with Epstein-Barr virus associated the follicular germinal center B cell lymphomas. ( 30964110 )
2019
18
Inflamed phenotype of splenic marginal zone B-cell lymphomas with expression of PD-L1 by intratumoral monocytes/macrophages and dendritic cells. ( 30967638 )
2019
19
Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms. ( 30972817 )
2019
20
PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B cell diffuse large B-cell lymphomas. ( 30975638 )
2019
21
CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. ( 31019670 )
2019
22
Rituximab as a dual therapeutic option for pemphigus and primary cutaneous B-cell lymphomas: two case reports. ( 31025498 )
2019
23
A modular transcriptome map of mature B cell lymphomas. ( 31039827 )
2019
24
Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy. ( 31056762 )
2019
25
DNA damage response inhibitor combinations exert synergistic antitumor activity in aggressive B cell lymphomas. ( 31064869 )
2019
26
Uncovering the role of hnRNP K, an RNA-binding protein, in B-cell lymphomas. ( 31077320 )
2019
27
The future of cell-free DNA testing to guide therapeutic decisions in B-cell lymphomas. ( 31082825 )
2019
28
Heterogeneity and coexistence of oncogenic mechanisms involved in HCV-associated B-cell lymphomas. ( 31092372 )
2019
29
Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art. ( 31099671 )
2019
30
Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2. ( 29931583 )
2019
31
Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas. ( 29946193 )
2019
32
High-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemma. ( 30181564 )
2019
33
Array-based profiling of the lymphoma cell DNA methylome does not unequivocally distinguish primary lymphomas of the central nervous system from non-CNS diffuse large B-cell lymphomas. ( 30284345 )
2019
34
Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. ( 30341058 )
2019
35
Epstein-Barr Virus Infection of Cell Lines Derived from Diffuse Large B-Cell Lymphomas Alters MicroRNA Loading of the Ago2 Complex. ( 30429351 )
2019
36
Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma. ( 30458196 )
2019
37
p53 expression in large B-cell lymphomas with MYC extra copies and CD99 expression in large B-cell lymphomas in relation to MYC status. ( 30496802 )
2019
38
Primary extranodal diffuse large B-cell lymphomas: Many sites, many entities? Clinico-pathological, immunohistochemical and cytogenetic study of 106 cases. ( 30553470 )
2018
39
Can We Exploit the Molecular Heterogeneity of Aggressive B Cell Lymphomas Into Effective New Therapies? ( 30555036 )
2018
40
Metabolic Reprogramming of Non-Hodgkin's B-Cell Lymphomas and Potential Therapeutic Strategies. ( 30564554 )
2018
41
Dissecting diffuse large B-cell lymphomas of the "not otherwise specified" type: the impact of molecular techniques. ( 30613381 )
2018
42
Comparison of protein-based cell-of-origin classification to the Lymph2Cx RNA assay in a cohort of diffuse large B-cell lymphomas in Malaysia. ( 28775174 )
2018
43
Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas. ( 28960532 )
2018
44
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. ( 29118007 )
2018
45
Obesity negatively impacts outcome in elderly female patients with aggressive B-cell lymphomas treated with R-CHOP: results from prospective trials of the German high grade non-Hodgkin's lymphoma trial group. ( 29193018 )
2018
46
Chemotherapy-induced differential cell cycle arrest in B-cell lymphomas affects their sensitivity to Wee1 inhibition. ( 29217775 )
2018
47
Vitamin D deficiency and supplementation in patients with aggressive B-cell lymphomas treated with immunochemotherapy. ( 29271084 )
2018
48
Very low-dose versus standard dose radiation therapy for indolent primary cutaneous B-cell lymphomas: A retrospective study. ( 29332711 )
2018
49
Novel insights into the disease dynamics of B-cell lymphomas in the Genomics Era. ( 29359812 )
2018
50
Computer-driven quantitative image analysis in the assessment of tumor cell and T cell features in diffuse large B cell lymphomas. ( 29362889 )
2018
Sources

Variations for B-Cell Lymphomas

About this section

Cosmic variations for B-Cell Lymphomas:

9 (show top 50) (show all 51)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6986772 TRAF2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.152A>G p.H51R 9:136898892-136898892 0
2 COSM10648 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.524G>A p.R175H 17:7675088-7675088 0
3 COSM44910 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.403T>A p.C135S 17:7675209-7675209 0
4 COSM10995 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.580C>T p.L194F 17:7674951-7674951 0
5 COSM4721653 RICTOR haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.3712C>T p.R1238* 5:38950136-38950136 0
6 COSM190567 RHOA haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.206T>C p.L69P 3:49368499-49368499 0
7 COSM5274 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.484G>C p.D162H 10:87933243-87933243 0
8 COSM6987562 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.331T>G p.W111G 10:87933090-87933090 0
9 COSM5036 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.202T>C p.Y68H 10:87925550-87925550 0
10 COSM30627 PIK3CA haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.3109G>A p.E1037K 3:179234266-179234266 0
11 COSM85940 MYD88 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.794T>C p.L265P 3:38141150-38141150 0
12 COSM6987557 MSH6 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.493T>C p.F165L 2:47795929-47795929 0
13 COSM2006760 KMT2D haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.12952C>T p.Q4318* 12:49030678-49030678 0
14 COSM6987497 KDM6A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.3406A>G p.M1136V 23:45083581-45083581 0
15 COSM6949886 HGF haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.986G>T p.W329L 7:81729659-81729659 0
16 COSM6948355 GRIN2A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.2453C>T p.A818V 16:9768993-9768993 0
17 COSM37031 EZH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.1936T>A p.Y646N 7:148811636-148811636 0
18 COSM37029 EZH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.1937A>C p.Y646S 7:148811635-148811635 0
19 COSM52944 DNMT3A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.2645G>A p.R882H 2:25234373-25234373 0
20 COSM6987563 DIS3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.2597A>C p.K866T 13:72761436-72761436 0
21 COSM6987564 CTCF haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.1282C>G p.Q428E 16:67621516-67621516 0
22 COSM12475 CDKN2A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.238C>T p.R80* 9:21971121-21971121 0
23 COSM22488 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.8494C>T p.R2832C 11:108345818-108345818 0
24 COSM21828 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.2932T>C p.S978P 11:108271261-108271261 0
25 COSM21829 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.8138G>A p.R2713K 11:108335096-108335096 0
26 COSM6987565 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.403T>A p.C135S 17:7675209-7675209 0
27 COSM6987567 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.403T>A p.C135S 17:7675209-7675209 0
28 COSM99914 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.524G>A p.R175H 17:7675088-7675088 0
29 COSM99023 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.128G>A p.R43H 17:7675088-7675088 0
30 COSM442676 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.2078G>A p.R693H 2:25234373-25234373 0
31 COSM376384 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.184C>T p.L62F 17:7674951-7674951 0
32 COSM99022 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.524G>A p.R175H 17:7675088-7675088 0
33 COSM3355994 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.524G>A p.R175H 17:7675088-7675088 0
34 COSM446026 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.3109G>A p.E1037K 3:179234266-179234266 0
35 COSM2006759 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.13762C>T p.Q4588* 12:49030678-49030678 0
36 COSM6987566 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.403T>A p.C135S 17:7675209-7675209 0
37 COSM1679502 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.580C>T p.L194F 17:7674951-7674951 0
38 COSM1640851 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.524G>A p.R175H 17:7675088-7675088 0
39 COSM6987496 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.3406A>G p.M1136V 23:45083581-45083581 0
40 COSM376383 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.301C>T p.L101F 17:7674951-7674951 0
41 COSM6987498 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.3427A>G p.M1143V 23:45083581-45083581 0
42 COSM6987569 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.124T>A p.C42S 17:7675209-7675209 0
43 COSM6987570 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.7T>A p.C3S 17:7675209-7675209 0
44 COSM376381 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.580C>T p.L194F 17:7674951-7674951 0
45 COSM99024 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.245G>A p.R82H 17:7675088-7675088 0
46 COSM5416224 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.818T>C p.L273P 3:38141150-38141150 0
47 COSM6986773 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.152A>G p.H51R 9:136898892-136898892 0
48 COSM4721652 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.3712C>T p.R1238* 5:38950136-38950136 0
49 COSM6987568 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.403T>A p.C135S 17:7675209-7675209 0
50 COSM376382 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.580C>T p.L194F 17:7674951-7674951 0
Sources

Expression for B-Cell Lymphomas

About this section
Search GEO for disease gene expression data for B-Cell Lymphomas.
Sources

Pathways for B-Cell Lymphomas

About this section

Pathways related to B-Cell Lymphomas according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
T cell receptor signaling pathway 38
Show member pathways
 12.46 BCL10 IRF4 MALT1 REL
2
Development EGFR signaling pathway 23
Show member pathways
 12.42 CCND1 CDKN1B MYC REL
3
NF-kappaB Signaling 4
12.4 BCL10 BCL6 IRF4 MALT1 PAX5 REL
4
MicroRNAs in cancer 38
12.32 CCND1 CDKN1B FOXP1 MIR17 MIR20A MYC
5
Development IGF-1 receptor signaling 23
Show member pathways
 12.28 CCND1 CCND3 CDKN1B MYC REL
6
Cell cycle 38 1
12.27 CCND1 CCND3 CDKN1B MYC
7
Viral carcinogenesis 38
12.19 CCND1 CCND3 CDKN1B REL
8
MAPK Signaling: Mitogen Stimulation Pathway 66
Show member pathways
 12.11 CCND1 CCND3 CDKN1B MYC
9
Cell cycle Role of SCF complex in cell cycle regulation 23
Show member pathways
 12.1 CCND1 CCND3 CDKN1B MYC
10
Transcriptional misregulation in cancer 38
12.1 BCL6 CDKN1B MYC PAX5 REL
11
Spinal Cord Injury 1
11.9 CCND1 CDKN1B MYC
12
Interleukin-4 and 13 signaling 67
11.87 BCL6 CCND1 IRF4 MYC
13
Glioblastoma Multiforme 65
11.85 CCND1 CDKN1B MYC
14
B cell receptor signaling pathway (KEGG) 38
Show member pathways
 11.81 BCL10 BCL6 IRF4 MALT1 MYC REL
15
Small cell lung cancer 38
11.77 CCND1 CDKN1B MYC
16
Retinoblastoma (RB) in Cancer 1
11.72 CCND1 CCND3 CDKN1B MYC
17
C-MYB transcription factor network 1
11.65 CCND1 CDKN1B MYC PAX5
18
E2F transcription factor network 1
11.64 CCND3 CDKN1B MYC
19
Human Thyroid Stimulating Hormone (TSH) signaling pathway 1
11.61 CCND3 CDKN1B MYC
20
DNA Damage Response (only ATM dependent) 1
11.61 BCL6 CCND1 CCND3 CDKN1B MYC
21
Regulation of Telomerase 1
11.59 CCND1 CDKN1B MYC
22
Validated targets of C-MYC transcriptional repression 1
11.54 CCND1 CDKN1B MYC
23
IL-2 Gene Expression in Activated and Quiescent T-Cells 65
Show member pathways
 11.52 CCND1 CDKN1B MYC REL
24
B Cell Development Pathways 66
11.47 BCL6 MME PAX5
25
DNA Damage Response 1
Show member pathways
 11.47 CCND1 CCND3 CDKN1B MIR17 MIR20A MYC
26
IL-7 Signaling Pathway 1
Show member pathways
 11.39 CCND1 CDKN1B MYC
27
miRNAs involved in DNA damage response 1
11.32 CCND1 CCND3 CDKN1B MYC
28
IL-10 Pathway 65
11.26 CCND1 CCND3 MYC
29
DNA damage_ATM/ATR regulation of G1/S checkpoint 23
11.2 CCND1 CCND3 MYC REL
Sources

GO Terms for B-Cell Lymphomas

About this section

Cellular components related to B-Cell Lymphomas according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CBM complex GO:0032449 8.62 BCL10 MALT1

Biological processes related to B-Cell Lymphomas according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.93 BCL6 CCND1 CCND3 MYC PAX5 REL
2 cytokine-mediated signaling pathway GO:0019221 9.84 BCL6 CCND1 IRF4 MYC
3 negative regulation of gene expression GO:0010629 9.81 MIR17 MIR20A MYC REL
4 response to estradiol GO:0032355 9.72 CCND1 CDKN1B MYC
5 G1/S transition of mitotic cell cycle GO:0000082 9.7 CCND1 CDKN1B MYC
6 negative regulation of toll-like receptor signaling pathway GO:0034122 9.56 IRF4 MIR17
7 response to molecule of bacterial origin GO:0002237 9.49 BCL10 MALT1
8 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.48 MIR17 MIR20A
9 negative regulation of B cell apoptotic process GO:0002903 9.43 BCL6 FOXP1
10 regulation of cyclin-dependent protein serine/threonine kinase activity GO:0000079 9.43 CCND1 CCND3 CDKN1B
11 response to fungus GO:0009620 9.4 BCL10 MALT1
12 re-entry into mitotic cell cycle GO:0000320 9.37 CCND1 MYC
13 regulation of T cell receptor signaling pathway GO:0050856 9.32 BCL10 MALT1
14 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.16 MIR17 MIR20A
15 positive regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045737 9.13 CCND1 CCND3 CDKN1B
16 positive regulation of cell cycle GO:0045787 8.92 CCND1 CCND3 CDKN1B MYC

Molecular functions related to B-Cell Lymphomas according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity GO:0003700 9.73 BCL6 FOXP1 IRF4 MYC PAX5 REL
2 kinase activator activity GO:0019209 9.16 BCL10 MALT1
3 protein self-association GO:0043621 9.13 BCL10 FOXP1 MALT1
4 cyclin-dependent protein serine/threonine kinase activity GO:0004693 8.32 CCND3
Sources

Sources for B-Cell Lymphomas

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....